Sisram Medical Yönetim

Yönetim kriter kontrolleri 2/4

Sisram Medical CEO'su Lior Dayan, Jun2017 tarihinde atandı, in görev süresi 7.42 yıldır. in toplam yıllık tazminatı $ 1.53M olup, şirket hissesi ve opsiyonları dahil olmak üzere 56.6% maaş ve 43.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.2% ine doğrudan sahiptir ve bu hisseler HK$ 2.98M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 7.3 yıldır.

Anahtar bilgiler

Lior Dayan

İcra Kurulu Başkanı

US$1.5m

Toplam tazminat

CEO maaş yüzdesi	56.6%
CEO görev süresi	7.4yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	7.3yrs

Son yönetim güncellemeleri

Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)

Jun 17

Recent updates

Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)

Jun 17

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

Apr 21

Does Sisram Medical (HKG:1696) Have A Healthy Balance Sheet?

Mar 28

Estimating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)

Mar 05

Take Care Before Diving Into The Deep End On Sisram Medical Ltd (HKG:1696)

Jan 23

Is Sisram Medical Ltd (HKG:1696) Potentially Undervalued?

Dec 29

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Nov 09

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

Oct 19

At HK$6.71, Is It Time To Put Sisram Medical Ltd (HKG:1696) On Your Watch List?

Sep 18

Sisram Medical (HKG:1696) Is Paying Out A Larger Dividend Than Last Year

Aug 14

Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Jun 16

Sisram Medical (HKG:1696) Shareholders Will Want The ROCE Trajectory To Continue

May 30

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Apr 19

Is Now The Time To Look At Buying Sisram Medical Ltd (HKG:1696)?

Mar 01

Sisram Medical (HKG:1696) Could Be Struggling To Allocate Capital

Jan 12

Sisram Medical (HKG:1696) Has A Rock Solid Balance Sheet

Dec 21

Should You Investigate Sisram Medical Ltd (HKG:1696) At HK$7.99?

Dec 01

Some Investors May Be Worried About Sisram Medical's (HKG:1696) Returns On Capital

Oct 14

Here's Why We Think Sisram Medical (HKG:1696) Is Well Worth Watching

Sep 28

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

Aug 25

Should You Think About Buying Sisram Medical Ltd (HKG:1696) Now?

Aug 01

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

May 19

Is Sisram Medical Ltd (HKG:1696) Trading At A 29% Discount?

May 03

If You Like EPS Growth Then Check Out Sisram Medical (HKG:1696) Before It's Too Late

Apr 11

Sisram Medical (HKG:1696) Is Experiencing Growth In Returns On Capital

Mar 17

Is Now An Opportune Moment To Examine Sisram Medical Ltd (HKG:1696)?

Nov 22

Calculating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)

Aug 22

Be Wary Of Sisram Medical (HKG:1696) And Its Returns On Capital

Jul 27

Here's Why We Think Sisram Medical Ltd's (HKG:1696) CEO Compensation Looks Fair

Jun 24

CEO Tazminat Analizi

Lior Dayan'un ücretlendirmesi Sisram Medical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$24m
Mar 31 2024	n/a	n/a	US$28m
Dec 31 2023	US$2m	US$863k	US$31m
Sep 30 2023	n/a	n/a	US$35m
Jun 30 2023	n/a	n/a	US$38m
Mar 31 2023	n/a	n/a	US$39m
Dec 31 2022	US$3m	US$1m	US$40m
Sep 30 2022	n/a	n/a	US$38m
Jun 30 2022	n/a	n/a	US$35m
Mar 31 2022	n/a	n/a	US$33m
Dec 31 2021	US$2m	US$767k	US$31m
Sep 30 2021	n/a	n/a	US$28m
Jun 30 2021	n/a	n/a	US$24m
Mar 31 2021	n/a	n/a	US$19m
Dec 31 2020	US$769k	US$596k	US$13m
Sep 30 2020	n/a	n/a	US$13m
Jun 30 2020	n/a	n/a	US$13m
Mar 31 2020	n/a	n/a	US$17m
Dec 31 2019	US$759k	US$606k	US$21m
Sep 30 2019	n/a	n/a	US$22m
Jun 30 2019	n/a	n/a	US$24m
Mar 31 2019	n/a	n/a	US$23m
Dec 31 2018	US$884k	US$560k	US$22m
Sep 30 2018	n/a	n/a	US$18m
Jun 30 2018	n/a	n/a	US$14m
Mar 31 2018	n/a	n/a	US$12m
Dec 31 2017	US$829k	US$361k	US$11m

Tazminat ve Piyasa: Lior 'nin toplam tazminatı ($USD 1.53M ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 336.37K ).

Tazminat ve Kazançlar: Lior 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Lior Dayan (54 yo)

7.4yrs

Görev süresi

US$1,526,000

Tazminat

Mr. Lior Moshe Dayan has been Chief Executive Officer and Executive Director at Sisram Medical Ltd since June 6, 2017 and its President since 2023 and is responsible for its overall and day-to-day manageme...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yi Liu	Executive Chairman	8.6yrs	US$27.00k	0.053% HK$ 792.5k
Lior Dayan	President	7.4yrs	US$1.53m	0.20% HK$ 3.0m
Jiahong Li	Chief Financial Officer	less than a year	Veri yok	Veri yok
Ran Ezioni	Chief Operating Officer	6.6yrs	Veri yok	Veri yok
Doron Yannai	VP of Finance	1.8yrs	Veri yok	Veri yok
Nikol Lev	Chief Information Officer	less than a year	Veri yok	Veri yok
Tal Rosen	Chief Marketing Officer	1.8yrs	Veri yok	Veri yok
Orit Segal	Chief People Officer	1.8yrs	Veri yok	Veri yok
Eyal David	President of ROW	1.8yrs	Veri yok	Veri yok
Itay Meir	EVP of R&D	1.8yrs	Veri yok	Veri yok
Keith Adams	President NA	1.8yrs	Veri yok	Veri yok
Qianli Fang	Company Secretary	2.8yrs	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim: 1696 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yi Liu	Executive Chairman	8.6yrs	US$27.00k	0.053% HK$ 792.5k
Lior Dayan	President	7.4yrs	US$1.53m	0.20% HK$ 3.0m
Heung Sang Fong	Independent Non-Executive Director	7.3yrs	US$32.00k	Veri yok
Yifang Wu	Non-Executive Director	8.1yrs	Veri yok	Veri yok
Chi Fung Chan	Independent Non-Executive Director	7.3yrs	US$32.00k	Veri yok
Jenny Chen	Independent Non-Executive Director	7.3yrs	US$32.00k	Veri yok
Kai Yu Liu	Independent Non-Executive Director	7.3yrs	US$32.00k	Veri yok
Rongli Feng	Non-Executive Director	4.3yrs	Veri yok	Veri yok

7.3yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1696 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.3 yıldır).

Sisram Medical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sisram Medical Ltd Announces Appointment of Jiahong LI New Chief Financial Officer, Effective 29 October 2024

Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)

Sisram Medical Ltd, Annual General Meeting, Jun 24, 2024

Sisram Medical Ltd, Annual General Meeting, Jun 28, 2023

Sisram Medical Ltd Announces Resignation of Mr. Guojun Bu from the Position of Executive Director of the Company with Effect from January 1, 2023

Less than half of directors are independent

Recent updates

Sisram Medical Ltd Announces the Launch of the Latest Edition of Alma Harmony

Sisram Medical Ltd Announces Appointment of Jiahong LI New Chief Financial Officer, Effective 29 October 2024

What Sisram Medical Ltd's (HKG:1696) 40% Share Price Gain Is Not Telling You

Investor sentiment improves as stock rises 24%

Sisram Medical Ltd Receives Product Approval from the National Medical Products Administration

First half 2024 earnings released: EPS: US$0.023 (vs US$0.04 in 1H 2023)

Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Dividend of HK$0.16 announced

Sisram Medical Ltd to Report First Half, 2024 Results on Aug 21, 2024

Sisram Medical Ltd Declares A Final Dividend, Payable on or Around 9 September 2024

Not Many Are Piling Into Sisram Medical Ltd (HKG:1696) Just Yet

Increases to CEO Compensation Might Be Put On Hold For Now at Sisram Medical Ltd (HKG:1696)

Sisram Medical Ltd, Annual General Meeting, Jun 24, 2024

Full year 2023 earnings released: EPS: US$0.067 (vs US$0.086 in FY 2022)

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

Does Sisram Medical (HKG:1696) Have A Healthy Balance Sheet?

Full year 2023 earnings released: EPS: US$0.067 (vs US$0.086 in FY 2022)

Sisram Medical Ltd Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2023

Sisram Medical Ltd to Report Fiscal Year 2023 Results on Mar 20, 2024

Estimating The Intrinsic Value Of Sisram Medical Ltd (HKG:1696)

Investor sentiment deteriorates as stock falls 20%

Now 21% overvalued

Take Care Before Diving Into The Deep End On Sisram Medical Ltd (HKG:1696)

Is Sisram Medical Ltd (HKG:1696) Potentially Undervalued?

Sisram Medical Ltd Announces the Registration Application of Profhilo

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Investor sentiment improves as stock rises 19%

Returns On Capital At Sisram Medical (HKG:1696) Have Stalled

At HK$6.71, Is It Time To Put Sisram Medical Ltd (HKG:1696) On Your Watch List?

First half 2023 earnings released: EPS: US$0.04 (vs US$0.044 in 1H 2022)

Upcoming dividend of HK$0.17 per share at 2.3% yield

Sisram Medical (HKG:1696) Is Paying Out A Larger Dividend Than Last Year

Sisram Medical Ltd Announces Final Ordinary Dividend for the Year Ended December 31, 2022, Payable 07 September 2023

Sisram Medical Announces the Launch of Alma Veil for the U.S. Market

Sisram Medical Ltd. Receives the Clearance from the U.S. Food and Drug Administration

Is There Now An Opportunity In Sisram Medical Ltd (HKG:1696)?

Investor sentiment improves as stock rises 16%

Sisram Medical (HKG:1696) Shareholders Will Want The ROCE Trajectory To Continue

Sisram Medical Ltd, Annual General Meeting, Jun 28, 2023

Is Sisram Medical (HKG:1696) Using Too Much Debt?

Investor sentiment improves as stock rises 18%

Full year 2022 earnings released: EPS: US$0.086 (vs US$0.069 in FY 2021)

Investor sentiment deteriorates as stock falls 16%

Is Now The Time To Look At Buying Sisram Medical Ltd (HKG:1696)?

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 19%

Sisram Medical (HKG:1696) Could Be Struggling To Allocate Capital

Sisram Medical Ltd Announces Resignation of Mr. Guojun Bu from the Position of Executive Director of the Company with Effect from January 1, 2023

Investor sentiment improved over the past week

Sisram Medical (HKG:1696) Has A Rock Solid Balance Sheet

Investor sentiment improved over the past week

Should You Investigate Sisram Medical Ltd (HKG:1696) At HK$7.99?

Less than half of directors are independent

Investor sentiment improved over the past week

Some Investors May Be Worried About Sisram Medical's (HKG:1696) Returns On Capital

Investor sentiment deteriorated over the past week

Here's Why We Think Sisram Medical (HKG:1696) Is Well Worth Watching

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

These 4 Measures Indicate That Sisram Medical (HKG:1696) Is Using Debt Safely

Sisram Medical Ltd Provides Revenue Guidance for the Year 2022

First half 2022 earnings released: EPS: US$0.044 (vs US$0.037 in 1H 2021)

Sisram Medical Ltd SHARE to Be Deleted from OTC Equity

Upcoming dividend of HK$0.16 per share

Sisram Medical Ltd to Report Q2, 2022 Results on Aug 19, 2022

Sisram Medical Ltd Declares Final Dividend for the Year Ended December 31, 2021, Payable on or Around 2 September 2022

Should You Think About Buying Sisram Medical Ltd (HKG:1696) Now?

Investor sentiment deteriorated over the past week

Sisram Medical Ltd Announces Phase IIb Clinical Result on Submental Fat Reduction of JS-001